Polymyalgia Rheumatica Behandlungsmarkt 2030 | Größe | Outlook teilen

Table of Content

1.Introduction

1.1.Market Introduction
1.2.Market Research Methodology
1.2.1.Research Process
1.2.2.Primary Research
1.2.3.Secondary Research
1.2.4.Data Collection Technique
1.2.5.Data Sources
1.3.Market Estimation Methodology
1.3.1.Limitations of the Study
1.4.Product Picture of Polymyalgia Rheumatica Treatment
1.5.Global Polymyalgia Rheumatica Treatment Market: Classification
1.6.Geographic Scope
1.7.Years Considered for the Study
1.8.Research Methodology in Brief
1.9.Parent Market Overview
1.10. Polymyalgia Rheumatica Treatment Market Regional Demand
1.11. Research Programs/Design
1.12. Market Breakdown and Data Triangulation Approach
1.13. Data Source
1.14. Secondary Sources
1.15. Primary Sources
1.16. Primary Interviews
1.17. Average Primary Breakdown Ratio

2.Market Dynamics

2.1.Drivers
2.1.1.Drivers
2.2.Restraints
2.2.1.Restraints
2.3.Opportunity
2.3.1.Impact Forces on Market Dynamics
2.3.2.Impact Forces During the Forecast Years
2.4.Industry Value Chain
2.4.1.Upstream Analysis
2.4.2.Downstream Analysis
2.4.3.Distribution Channel
2.4.4.Direct Channel
2.4.5.Indirect Channel
2.5.Potential Customers
2.6.Manufacturing/Operational Cost Analysis
2.7.Pricing Analysis by Region
2.8.Key Technology Landscape
2.9.Porter\'s Analysis
2.9.1.Supplier Power
2.9.2.Buyer Power
2.9.3.Substitution Threat
2.9.4.Threat from New Entry
2.9.5.Competitive Rivalry
2.10. PESTEL Analysis
2.10.1. Political Factors
2.10.2. Economic Factors
2.10.3. Social Factors
2.10.4. Technological Factors
2.10.5. Environmental Factors
2.10.6. Legal Factors

3.Global Polymyalgia Rheumatica Treatment Market Segmentation, by Revenue (USD Million), (2023-2030)

3.1.By Drug Class
3.1.1.Corticosteroids
3.1.2.Disease-Modifying Anti-Rheumatic Drugs (DMARDS)
3.1.3.Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)
3.1.4.Others
3.2.By End User
3.2.1.Hospitals
3.2.2.Homecare
3.2.3.Specialty Clinics
3.2.4.Others

4.Global Polymyalgia Rheumatica Treatment Market Overview, By Region

4.1. North America Polymyalgia Rheumatica Treatment Market Revenue (USD Million), by Countries, (2023-2030)
4.1.1. U.S.
4.1.1.1.By Treatment Type
4.1.1.2.By End User
4.1.2.Canada
4.1.3.Mexico
4.2.Europe Polymyalgia Rheumatica Treatment Market Revenue (USD Million), by Countries, (2023-2030)
4.2.1.Germany
4.2.2.France
4.2.3.UK
4.2.4.Spain
4.2.5.Russia
4.2.6.Italy
4.2.7.BENELUX
4.3.Asia Pacific Polymyalgia Rheumatica Treatment Market Revenue (USD Million), by Countries, (2023-2030)
4.3.1. China
4.3.2. Japan
4.3.3. Australia
4.3.4. South Korea
4.3.5. India
4.3.6. ASEAN
4.4.Latin America Polymyalgia Rheumatica Treatment Market Revenue (USD Million), by Countries, (2023-2030)
4.4.1. Brazil
4.4.2. Argentina
4.4.3. Chile
4.5.Middle East and Africa Polymyalgia Rheumatica Treatment Market Revenue (USD Million), by Countries, (2023-2030)
4.5.1.GCC
4.5.2.Turkey
4.5.3.South Africa

5.Global Polymyalgia Rheumatica Treatment Market Revenue: Competitive Analysis, 2022

5.1.Key Strategies by Players
5.2.Revenue (USD Million) and Market Share (%), By Manufacturers, 2022
5.3.Player Positioning by Market Players, 2022

6.Competitive Analysis

6.1.Regeneron Pharmaceuticals Inc.
6.1.1.Business Overview
6.1.2.Business Financials (USD Million)
6.1.3.Product Category, Type, and Specification
6.1.4.Main Business/Business Overview
6.1.5.Geographical Analysis
6.1.6.Recent Development
6.1.7.SWOT Analysis
6.2.Sanofi
6.3.GSK plc
6.4.Merck & Co., Inc.
6.5.Pfizer Inc.
6.6.Centurion Healthcare Private Limited
6.7.Hovione
6.8.MODASA, Pharmaceuticals Pvt. Ltd.
6.9.F. Hoffmann-La Roche Ltd.
6.10.AbbVie Inc.

7.Market Research Findings & Conclusion

Disclaimer